Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy

Xin Zheng,1 Kun Qian2,3 1Department of Hepatopancreatobiliary Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, People’s Republic of China; 2Department of Radiology, Union Hospital, Tongji Medical College, Huaz...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zheng X, Qian K
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-06-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	hepatic arterial infusion chemotherapy apatinib camrelizumab hepatocellular carcinoma recurrent
Online Access:	https://www.dovepress.com/hepatic-arterial-infusion-chemotherapy-combined-apatinibcamrelizumab-f-peer-reviewed-fulltext-article-JHC
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
by: Kugeluke Yalikun, et al.
Published: (2025-05-01)

Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial
by: Lujun Shen, et al.
Published: (2025-05-01)

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01)

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study
by: Wu C, et al.
Published: (2025-07-01)

Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements
by: Wei Xu, et al.
Published: (2025-05-01)

Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma: A Three-Dimensional Visualization Perspective
by: Tan Y, et al.
Published: (2025-04-01)

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update
by: Shiguang Chen, et al.
Published: (2025-12-01)

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma
by: Zhang J, et al.
Published: (2025-05-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma
by: Li J, et al.
Published: (2025-02-01)

Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
by: Ji Yeon Lee, et al.
Published: (2024-12-01)

Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma
by: Xia Y, et al.
Published: (2025-07-01)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
by: Mingtao Liu, et al.
Published: (2020-04-01)

Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)

Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report
by: Miao Li, et al.
Published: (2024-12-01)

Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review
by: Ying Wu, et al.
Published: (2025-03-01)

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma
by: Yu-zhe Cao, et al.
Published: (2024-11-01)

Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
by: Chia-Ling Chiang, et al.
Published: (2025-06-01)

Anxiety is a risk prognosis factor for hepatocellular carcinoma with portal vein tumor thrombus who underwent hepatic arterial infusion chemotherapy: a propensity score-matching cohort study
by: Hao-yang Tan, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma
by: Huimin You, et al.
Published: (2022-12-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
by: Zhonghua Zhao, et al.
Published: (2024-12-01)

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab
by: Chang-Fu Liu, et al.
Published: (2025-08-01)

Single‐Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy
by: YeXing Huang, et al.
Published: (2025-02-01)

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial
by: Xue-Feng Kan, et al.
Published: (2025-05-01)

Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)Research in context
by: Wei Gao, et al.
Published: (2025-05-01)

Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies
by: Hao-Huan Tang, et al.
Published: (2025-04-01)

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma
by: Chunyu Lin, et al.
Published: (2025-06-01)

Induction hepatic arterial infusion chemotherapy followed by surgery for hepatocellular carcinoma with massive portal vein tumor thrombosis: a case series of 20 patients
by: Yuta Kimura, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
by: Zizhuo Wang, et al.
Published: (2025-01-01)

Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma
by: Tongshan Wang, et al.
Published: (2024-12-01)

Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy
by: Rui Xing, et al.
Published: (2025-07-01)

Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)
by: Hang Yuan, et al.
Published: (2025-07-01)

Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching Analysis
by: Zhong S, et al.
Published: (2025-03-01)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States
by: Qiuling Zhao, et al.
Published: (2025-05-01)

Radiotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion chemotherapy of RALOX versus FOLFOX for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score-matching cohort study
by: Hao-yang Tan, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01)

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
by: Baiguo Xu, et al.
Published: (2025-06-01)